Search

Displaying results 5051 - 5060 of 8974 in total
  1. Drug

    TGAAC09

    go.drugbank.com/drugs/DB06363
    Investigational

    tgAAC09 is an investigational vaccine that utilizes an AAV vector to deliver genes that encode HIV proteins. … It was under investigation in clinical trials NCT00482027 and NCT00888446 for the treatment of HIV Infection.

  2. Drug

    Tilarginine

    go.drugbank.com/drugs/DB11815
    ApprovedInvestigationalWithdrawn

    Tilarginine has been investigated for the basic science, treatment, and diagnostic of Obesity, Type 2 Diabetes, Ocular Physiology, and Regional Blood Flow.

  3. Drug

    Ferrous glycine sulfate

    go.drugbank.com/drugs/DB14501
    Approved

  4. Drug

    Boscalid

    go.drugbank.com/drugs/DB12792
    ApprovedWithdrawn

    Boscalid has been investigated for the treatment of OSDI, Glaucoma, Staining, Schirmers, and Disease Severity, among others.

  5. Drug

    Peginterferon alfacon-1

    go.drugbank.com/drugs/DB05860
    Experimental

    PEGylation is a technology for the chemical attachment of polyethylene glycol (PEG) polymer chains to a broad range of drug substances such as peptides and proteins including antibody fragments; small … [Infergen] is a bio-engineered type I interferon alpha that is FDA-approved for the treatment of patients with chronic hepatitis C infections.

  6. Drug

    Rhein

    go.drugbank.com/drugs/DB13174
    Experimental

    It is known to have hepatoprotective, nephroprotective, anti-cancer, anti-inflammatory, and several other protective effects.

  7. Drug

    Cusatuzumab

    go.drugbank.com/drugs/DB15100
    Investigational

    syndrome (MDS) in patients unsuitable for chemotherapy. … CD70 is a ligand expressed on the surface of activated lymphocytes and mature dendritic cells that, in its binding to CD27 receptors, plays an important role in cell proliferation and survival.

  8. Drug

    SYN-101

    go.drugbank.com/drugs/DB05958
    Experimental

    SYN-101 is an investigational antibody-drug conjugate developed for the treatment of cancer. … SYN101 is comprised of an immune cell specific antibody linked to an ALK5 inhibitor payload to selectively block TGF-b signalling in immune cells.

  9. Drug

    NS-3728

    go.drugbank.com/drugs/DB05835
    Experimental

    NS3728 is an orally active chloride channel blocker for the treatment of cancer.

  10. Drug

    CTS-21166

    go.drugbank.com/drugs/DB06073
    Investigational

    CTS-21166 is a small-molecule beta-secretase inhibitor, which is being developed as a disease-modifying treatment for Alzheimer's disease. … CTS-21166 is the only BACE1 inhibitor that has passed Phase I clinical trial thus far.